Neumora Therapeutics announced Phase 3 trial results for its major depressive disorder (MDD) drug, navacaprant. The KOASTAL-1 study, the first of three in the pivotal KOASTAL program, did not meet its primary endpoint of a statistically significant reduction in depressive symptoms, measured by the MADRS total score, compared to placebo. However, a potential efficacy signal was observed in female participants, prompting further analysis. Navacaprant demonstrated a generally acceptable safety profile comparable to placebo.
This news carries implications for the MDD treatment landscape. While the overall results are a setback for Neumora, the efficacy signal observed in the female subgroup presents a critical avenue for investigation. This potential sex-specific response could lead to a more personalized approach to MDD treatment, particularly given the higher prevalence of depression in women. Further investigation into this subgroup could reveal valuable insights into the underlying mechanisms of MDD and inform the development of more targeted therapies.
In the KOASTAL-1 study, 383 adult patients with MDD received either navacaprant 80 mg or a placebo. Both the navacaprant and placebo groups showed a similar reduction in MADRS total score at week 6 (-12.5). A statistically significant improvement in anhedonia, as measured by the SHAPS total score, was observed in female participants receiving navacaprant compared to those receiving placebo. Importantly, navacaprant’s safety profile was comparable to placebo, with no serious adverse events reported and no increased risk of suicidal ideation or behavior.
The future of navacaprant hinges on further analysis of the KOASTAL-1 data, particularly the female subgroup findings, and the outcomes of the ongoing KOASTAL-2 and KOASTAL-3 trials. If subsequent trials confirm the efficacy signal in women, Neumora may be able to pursue a more targeted development strategy. This approach could involve focusing on a female-specific indication or refining the drug’s formulation or dosage regimen. The results of these ongoing studies, combined with the additional analyses, will determine the next steps for the navacaprant program and its potential role in addressing the significant unmet need in MDD treatment.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
